Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris
- 25 April 2006
- journal article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 155 (2), 330-336
- https://doi.org/10.1111/j.1365-2133.2006.07305.x
Abstract
Background BAFF [B-cell activating factor belonging to the tumour necrosis factor (TNF) family] is a member of the TNF superfamily that regulates B-lymphocyte proliferation and survival. It has been demonstrated that increased levels of soluble BAFF are associated with systemic autoimmunity in patients with systemic lupus erythematosus, rheumatoid arthritis and Sjögren's syndrome, and in animal models of spontaneous autoimmune diseases. However, the significance of circulating BAFF in autoimmune bullous diseases is unknown. Objectives To examine whether BAFF levels are elevated in the autoimmune blistering diseases pemphigus vulgaris (PV) and bullous pemphigoid (BP). Methods We examined sera obtained from 21 patients with PV, 39 patients with BP and 22 healthy donors. We performed enzyme-linked immunosorbent assays for soluble BAFF and each disease-specific antibody: antidesmoglein-3 antibody for PV and anti-BP180 antibody for BP. Results Significant elevations of serum BAFF levels were found in the patients with BP, but not with PV. There was apparently no significant association between the serum BAFF levels and titres of anti-BP180 antibodies in the patients with BP. However, serum BAFF levels tended to be more elevated in patients with a shorter disease duration. There was a tendency that BAFF levels increased before the anti-BP180 antibody levels increased at the onset of BP and quickly decreased in response to treatment. Conclusions BAFF may be a useful marker for early activation of an autoimmune diathesis and may play a critical role in triggering activation of self-antigen-driven autoreactive B cells in BP.Keywords
This publication has 38 references indexed in Scilit:
- Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximabBritish Journal of Dermatology, 2005
- Infliximab in the management of severe pemphigus vulgarisBritish Journal of Dermatology, 2005
- BAFF: A fundamental survival factor for B cellsNature Reviews Immunology, 2002
- Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseasesArthritis & Rheumatism, 2001
- TNFα and IL‐6 are mediators in the blistering process of pemphigusInternational Journal of Dermatology, 2001
- In Vitro and In Vivo Expression of Interleukin-1α and Tumor Necrosis Factor-α mRNA in Pemphigus Vulgaris: Interleukin-1α and Tumor Necrosis Factor-α are Involved in AcantholysisJournal of Investigative Dermatology, 2000
- Blister Fluid Cytokines in Cutaneous Inflammatory Bullous DisordersActa Dermato-Venereologica, 1999
- Increased serum IL-6, TNF-alpha and IL-10 levels in patients with bullous pemphigoid: relationships with disease activityJournal of the European Academy of Dermatology and Venereology, 1999
- Increased serum IL-6, TNF-alpha and IL-10 levels in patients with bullous pemphigoid: relationships with disease activityJournal of the European Academy of Dermatology and Venereology, 1999
- Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: relationships with disease intensityBritish Journal of Dermatology, 1998